COMPARE · Reviewed August 3, 2026
CON vs PACS
Verdict: Side-by-side breakdown using the Bull Rankings model. CON scored 71.3, PACS scored 69.4 — CON leads.
Compare another set
CON
Concentra Group Holdings Parent, Inc.
71.3
$31.48 · $4.0B
fundamentals as of
Score gap
1.9
CON leads
PACS
PACS Group, Inc.
69.4
$45.29 · $7.2B
fundamentals as of
The model, pillar by pillar (0–100 each)
CON
stronger →← stronger
PACS
73
Qualityreturns · margins · balance sheet
60
86
Growthrevenue & earnings expansion
100
58
Valuevaluation vs sector peers
56
CON is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
CON
PACS
$211mC
FCF
$151mC
+15.5%B+
Rev
+22.2%A-
4.68D
D/E
3.36D
22.7xB+
P/E
29.2xB
1.65C+
PEG
1.35B
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
Valuation · DCF cross-check
CON
PACS
25% below
Price vs fair valuelower is cheaper
207% above
~1%/yr
Growth the price implies10-yr FCF · lower = less priced in
~33%/yr
+19%
1-yr DCF upside
-68%
+34%
5-yr DCF upside
-67%
+59%
10-yr DCF upside
-66%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
CON
Why this score
- Durable high returns
- Short track record
PACS
Why this score
- Diluting shareholders
- Short track record
The companies
CONConcentra Group Holdings Parent, Inc.
Why now
Medical Care Facilities · market cap $4.0b. 4% off the 52-week high of $32.86. Revenue growing +15%, comfortably above the S&P median. 8 sell-side analysts publish a mean 1-yr target of $33.38 (implying +6% upside).
Moat
ROE 42% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 119% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
D/E 4.68 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer.
PACSPACS Group, Inc.
Why now
Medical Care Facilities · market cap $7.2b. 6% off the 52-week high of $48.00. Revenue growing +22%, comfortably above the S&P median. 6 sell-side analysts publish a mean 1-yr target of $52.67 (implying +16% upside).
Moat
ROE 24% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately.
Risk
D/E 3.36 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Net margin 4.5% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.